Cell-intrinsic PD-1 and PD-L1 were found to be expressed in a large variety of cancer cells, with particularly high PD-1 expression in 13 tumor types and 40 tumor cell lines, including cervical cancer ...
Although triple-negative breast cancers are still challenging to treat, the development of novel neoadjuvant chemotherapy combined with immune checkpoint antibodies is promising. Our group developed ...
PD-1 checkpoint proteins on T cells (blue) can bind to two different receptors: PD-L1 and PD-L2. There are many ways to climb a mountain. This saying especially rings true in cancer research, where ...
The FDA is asking outside advisers to weigh in on the scope of current and potential stomach cancer approvals for immunotherapies made by Bristol Myers Squibb, Merck & Co and BeiGene. (Sarah ...
Efficacy and safety of LM-108, an anti-CCR8 monoclonal antibody, in combination with an anti-PD-1 antibody in patients with gastric cancer: Results from phase 1/2 studies. This is an ASCO Meeting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results